Replimune Group, Inc. (REPL)
Automate Your Wheel Strategy on REPL
With Tiblio's Option Bot, you can configure your own wheel strategy including REPL - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol REPL
- Rev/Share 0.0161
- Book/Share 3.6793
- PB 2.775
- Debt/Equity 0.2267
- CurrentRatio 6.9399
- ROIC -0.7109
- MktCap 796950188.0
- FreeCF/Share -2.4898
- PFCF -3.4976
- PE -3.3345
- Debt/Assets 0.1626
- DivYield 0
- ROE -0.6934
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 3
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | REPL | H.C. Wainwright | Neutral | Buy | -- | $12 | Oct. 27, 2025 |
| Upgrade | REPL | Wedbush | Neutral | Outperform | -- | $18 | Oct. 20, 2025 |
| Upgrade | REPL | JP Morgan | Underweight | Neutral | -- | -- | Oct. 20, 2025 |
| Upgrade | REPL | Leerink Partners | Market Perform | Outperform | -- | $13 | Oct. 20, 2025 |
| Upgrade | REPL | Piper Sandler | Neutral | Overweight | -- | $13 | Oct. 20, 2025 |
| Downgrade | REPL | JP Morgan | Neutral | Underweight | -- | -- | Sept. 19, 2025 |
| Upgrade | REPL | Cantor Fitzgerald | Neutral | Overweight | -- | -- | July 30, 2025 |
| Downgrade | REPL | BMO Capital Markets | Outperform | Underperform | -- | $2 | July 23, 2025 |
| Downgrade | REPL | Barclays | Overweight | Equal Weight | -- | $3 | July 23, 2025 |
| Downgrade | REPL | H.C. Wainwright | Buy | Neutral | -- | -- | July 23, 2025 |
News
REPL Stock Plunges 54% in 3 Months After FDA Rejects Skin Cancer Drug
Published: September 24, 2025 by: Zacks Investment Research
Sentiment: Negative
Replimune stock dives 54% over three months after the FDA rejects its RP1/Opdivo melanoma drug filing, delaying its first potential product launch.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - REPL
Published: September 23, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Sept. 23, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Replimune Group, Inc. ("Replimune" or the "Company") (NASDAQ: REPL).
Read More
Investors in Replimune Group, Inc. Should Contact Levi & Korsinsky Before September 22, 2025 to Discuss Your Rights – REPL
Published: September 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Replimune Group, Inc. ("Replimune Group, Inc." or the "Company") (NASDAQ: REPL) of a class action securities lawsuit.
Read More
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune
Published: September 22, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)---- $REPL #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL) and reminds investors of the September 22, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.
Read More
REPL Deadline: REPL Investors with Losses in Excess of $100K Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit Filed by The Rosen Law Firm
Published: September 22, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Sept. 22, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Replimune Group, Inc. (NASDAQ: REPL) between November 22, 2024 and July 21, 2025, both dates inclusive (the "Class Period"), of the important September 22, 2025 lead plaintiff deadline in the securities class action first filed by the Firm.
Read More
REPLIMUNE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Replimune Group, Inc. and Encourages Investors to Contact the Firm Before September 22nd
Published: September 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
Allegedly, defendants overstated IGNYTE trial prospects despite issues that led the FDA to deem it inadequate, misleading investors and causing losses.
Read More
Replimune Group, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. September 22, 2025 Deadline to file Lead Plaintiff Motion.
Published: September 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
Investors can contact the law firm at no cost to learn more about recovering their losses
Read More
BREAKING: Replimune Shares Drop Over 40%; Investors Should Contact Block & Leviton By September 22nd To Join Securities Fraud Lawsuit
Published: September 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
BOSTON, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Block & Leviton reminds investors that a securities fraud lawsuit has been filed against Replimune Group, Inc. (Nasdaq: REPL) and certain of its executives.
Read More
Replimune Provides Update Following Type A Meeting with FDA
Published: September 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
WOBURN, Mass., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that the company completed a Type A meeting with the U.S. Food and Drug Administration (FDA) on September 16th to discuss the complete response letter (CRL) for the Company's Biologics License Application (BLA) for RP1 in combination with nivolumab for the treatment of advanced melanoma.
Read More
REPL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Replimune Group, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Published: September 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Replimune Group, Inc. (“Replimune” or “the Company”) (NASDAQ: REPL) and certain of its officers.
Read More
Investor Lawsuit Targets Replimune (REPL) After FDA Deems RP1 Trial Inadequate - Hagens Berman
Published: September 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
REPL Investors with Losses Encouraged to Contact the Firm Before Sept. 22nd Deadline REPL Investors with Losses Encouraged to Contact the Firm Before Sept. 22nd Deadline
Read More
Investor Lawsuit Targets Replimune (REPL) After FDA Deems RP1 Trial Inadequate - Hagens Berman
Published: September 15, 2025 by: GlobeNewsWire
Sentiment: Neutral
REPL Investors with Losses Encouraged to Contact the Firm Before Sept. 22nd Deadline REPL Investors with Losses Encouraged to Contact the Firm Before Sept. 22nd Deadline
Read More
REPL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Replimune Group, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Published: September 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Replimune Group, Inc. (“Replimune” or “the Company”) (NASDAQ: REPL) and certain of its officers.
Read More
Replimune (REPL) Faces Investor Lawsuit After FDA Blocks Cancer Drug Approval - Hagens Berman
Published: September 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL) is under fire from investors following a dramatic regulatory setback that sent its stock into freefall.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPL
Published: September 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Read More
REPL 2-WEEK DEADLINE ALERT: Replimune (REPL) Faces Investor Lawsuit After FDA Blocks Cancer Drug Approval - Hagens Berman
Published: September 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL) is under fire from investors following a dramatic regulatory setback that sent its stock into freefall.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - REPL
Published: September 08, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Sept. 8, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Replimune Group, Inc. ("Replimune" or the "Company") (NASDAQ: REPL).
Read More
REPLIMUNE GROUP, INC. (NASDAQ: REPL) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Replimune Group, Inc. Investors of Upcoming Deadline
Published: September 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company.
Read More
Replimune (REPL) Faces Investor Lawsuit After FDA Blocks Cancer Drug Approval - Hagens Berman
Published: September 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL) is under fire from investors following a dramatic regulatory setback that sent its stock into freefall.
Read More
Investor Lawsuit Targets Replimune (REPL) After FDA Deems RP1 Trial Inadequate - Hagens Berman
Published: September 04, 2025 by: PRNewsWire
Sentiment: Neutral
SAN FRANCISCO , Sept. 4, 2025 /PRNewswire/ -- A new securities class action lawsuit has been filed against Replimune Group, Inc. (NASDAQ: REPL) and its executives.
Read More
Shareholders that lost money on Replimune Group, Inc. (REPL) should contact Levi & Korsinsky about pending Class Action - REPL
Published: September 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Replimune Group, Inc. ("Replimune Group, Inc." or the "Company") (NASDAQ: REPL) of a class action securities lawsuit.
Read More
Class Action Reminder for REPL Investors: Kessler Topaz Meltzer & Check, LLP Reminds Replimune Group, Inc. (REPL) Investors of Securities Fraud Class Action Lawsuit
Published: September 02, 2025 by: PRNewsWire
Sentiment: Neutral
RADNOR, Pa. , Sept. 2, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Replimune Group, Inc. ("Replimune") (NASDAQ: REPL) on behalf of those who purchased or otherwise acquired Replimune securities between November 22, 2024, and July 21, 2025, inclusive (the "Class Period").
Read More
REPLIMUNE GROUP, INC. (NASDAQ: REPL) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Replimune Group, Inc. Investors of Upcoming Deadline
Published: September 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company.
Read More
Replimune (REPL) Faces Investor Lawsuit Following 77% Stock Crash After FDA Rejects Key Drug - Hagens Berman
Published: September 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Hagens Berman is investigating claims alleged in a new securities class action against Replimune Group, Inc. (NASDAQ: REPL) and its executives after the company's stock plummeted following the FDA's rejection of its leading cancer drug, RP1.
Read More
Faruqi & Faruqi Reminds Replimune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 22, 2025 - REPL
Published: August 29, 2025 by: PRNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Replimune To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Replimune between November 22, 2024 and July 21, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , Aug. 29, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Replimune Group, Inc. ("Replimune" …
Read More
Replimune (REPL) Faces Investor Lawsuit Following 77% Stock Crash After FDA Rejects Key Drug - Hagens Berman
Published: August 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Hagens Berman is investigating claims alleged in a new securities class action against Replimune Group, Inc. (NASDAQ: REPL) and its executives after the company's stock plummeted following the FDA's rejection of its leading cancer drug, RP1. The lawsuit alleges that Replimune misled investors by overstating the drug's trial data and failing to disclose critical regulatory risks.
Read More
ROSEN, THE FIRST FILING FIRM, Encourages Replimune Group, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – REPL
Published: August 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Replimune Group, Inc. (NASDAQ: REPL) between November 22, 2024 and July 21, 2025, both dates inclusive (the “Class Period”), of the important September 22, 2025 lead plaintiff deadline in the securities class action first filed by the Firm.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPL
Published: August 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Replimune Group, Inc. (“Replimune” or the “Company”)(NASDAQ: REPL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - REPL
Published: August 22, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Aug. 22, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Replimune Group, Inc. ("Replimune" or the "Company")(NASDAQ: REPL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Read More
Shareholders that lost money on Replimune Group, Inc.(REPL) should contact Levi & Korsinsky about pending Class Action - REPL
Published: August 22, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Aug. 22, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Replimune Group, Inc. ("Replimune Group, Inc." or the "Company") (NASDAQ: REPL) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Replimune Group, Inc. investors who were adversely affected by alleged securities fraud between November 22, 2024 and July 21, 2025.
Read More
About Replimune Group, Inc. (REPL)
- IPO Date 2018-07-20
- Website https://www.replimune.com
- Industry Biotechnology
- CEO Sushil Patel
- Employees 479